News headlines about SteadyMed (NASDAQ:STDY) have been trending positive recently, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SteadyMed earned a news sentiment score of 0.36 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.6615610343791 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several equities analysts have weighed in on the stock. Zacks Investment Research upgraded shares of SteadyMed from a “hold” rating to a “strong-buy” rating and set a $3.25 target price on the stock in a report on Thursday, April 12th. JMP Securities reiterated a “buy” rating on shares of SteadyMed in a report on Wednesday, January 10th.
NASDAQ:STDY traded up $0.19 on Thursday, hitting $3.19. The stock had a trading volume of 6,989 shares, compared to its average volume of 15,143. The firm has a market capitalization of $82.38, a price-to-earnings ratio of -7.42 and a beta of 0.53. SteadyMed has a 1-year low of $2.80 and a 1-year high of $7.50.
SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and other diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, pre-filled, water-resistant, and disposable parenteral drug administration technology.
Receive News & Ratings for SteadyMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SteadyMed and related companies with MarketBeat.com's FREE daily email newsletter.